R.A. Session II - Nov 10, 2022 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
Director, 10%+ Owner
Signature
/s/ Kamran Alam, Attorney-in-Fact
Stock symbol
TSHA
Transactions as of
Nov 10, 2022
Transactions value $
$0
Form type
4
Date filed
12/23/2022, 03:15 PM
Previous filing
Feb 25, 2022
Next filing
Mar 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Award $0 +200K $0.00 200K Nov 10, 2022 Common Stock 200K $1.95 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors on November 10, 2022.
F2 25% of the total number of shares underlying the option shall vest and become exercisable on November 10, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.